Vaccinex, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vaccinex, Inc. - overview
Established
1895
Location
Rochester, NY, US
Primary Industry
Biotechnology
About
Founded in 1895 and based in New York, US, Vaccinex, Inc. operates as a clinical-stage immunotherapy company that develops antibody therapeutics for neurological diseases and cancer. The company was founded by its CEO, Maurice Zauderer. In August 2018, Vaccinex, Inc.
raised USD 40 million in an IPO, selling 3. 33 million shares at USD 12 per share, within the expected USD 12–15 range. Vaccinex, Inc. granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of common stock as part of the listing.
The company trades on the Nasdaq under the ticker symbol VCNX. Vaccinex develops drugs for treating cancer, neurodegenerative diseases, and autoimmune disorders through the inhibition of semaphorin 4D (SEMA4D). The firm’s lead drug candidate is pepinemab, which is a monoclonal antibody that blocks a protein called SEMA4D. The company offers the ActivMab platform, a drug discovery platform that discovers and develops antibodies for various chronic neurological disorders such as Alzheimer’s and Huntington’s disease.
Current Investors
Pan Atlantic Bank and Trust Limited., Biocon Ltd, Teva Pharmaceuticals Industries Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.vaccinex.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.